NovoCure (NVCR) Stock Price

$18.86 0.6%

Sign up
to add to portfolio

AI Score

Sell
  • Alternative

    3
  • Fundamental

    2
  • Technical

    5

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on NovoCure, AI stock picks, stock alerts and much more.

Sign up

NVCR AI Stock Analysis

AI stock analysis for NVCR is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like NovoCure (NVCR) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

NovoCure (NVCR) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of NovoCure (NVCR), currently trading at $18.86, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About NVCR

LSE
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.

  • Symbol

    NVCR

  • Market

    NASDAQ

  • Industry

    Medical - Instruments & Supplies

  • Market Cap

    2.1B

Similar Stocks

XRAY Dentsply
XRAY
$14.93
4.5%
5
ISRG Intuitive Surgical
ISRG
$491.8
3.2%
6
LMAT LeMaitre Vascular
LMAT
$83.05
1%
6
ICUI ICU Medical
ICUI
$140.2
2.9%
4
HOLX Hologic
HOLX
$61.32
1.6%
5

NVCR Alternative Data

Web Traffic

NovoCure receives an estimated 37297 monthly visitors to novocure.com.

  • Web Traffic

    37297

  • Change from Previous Month

    44.8%

  • 3 Month Change

    11.1%

  • YoY Change

    11.1%

News Mentions

NovoCure was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    100%

  • 3 Month Change

    0%

Reddit Mentions

NovoCure has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

Twitter Followers

NovoCure has 2,721 Twitter Followers on its main Twitter (also known as X) account.

  • Twitter Followers

    2721

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0.2%

  • YoY Change

    0.2%

LinkedIn Followers

56,690 are following NovoCure on LinkedIn, up by 1.9% over the last month.

  • LinkedIn Followers

    56690

  • Daily Change

    0.1%

  • 1 Month Change

    1.9%

  • 3 Month Change

    6.4%

Job Postings

NovoCure currenly has an estimated 63 open job postings, up by 8.6% over the last month.

  • Job Postings

    63

  • Daily Change

    3.1%

  • 1 Month Change

    8.6%

  • 3 Month Change

    40%

  • YoY Change

    40%

LinkedIn Employees

According to LinkedIn, NovoCure has 1,399 employees, up by 0.1% over the last month.

  • LinkedIn Employees

    1399

  • Daily Change

    0%

  • 1 Month Change

    0.1%

  • 3 Month Change

    1.1%

  • YoY Change

    1.1%

Business Outlook

According to employee reviews, the business outlook among employees at NovoCure is 37 out of 100 (bearish).

  • Business Outlook

    37

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

NVCR Financials

NVCR Key Metrics
  • Total Revenue

    $161.3M

  • Net Income

    -$65.9M

  • Earnings per Share

    -$0.61

  • Free cash flow

    -$12.4M

  • EBITDA

    -$10.5M

  • EBITDA Ratio

    -0.0652524

  • Total Assets

    $1.2B

NVCR 2-year Revenue & Income
NVCR 2-year Free Cash Flow

NVCR Technicals

NVCR SMA
NVCR RSI

FAQ

What's the current price of NovoCure (NVCR) Stock?
The price of an NovoCure (NVCR) share is $18.86.

What's the market cap of NovoCure?
The current market cap of NovoCure is 2.1B.

Should I buy or sell NVCR?
NovoCure exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.

Is NovoCure a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in NovoCure stock. There are several bearish signals and market challenges that could negatively impact NovoCure's future performance, suggesting that caution should be exercised before making any investment decisions.

Is now a good time to buy NovoCure (NVCR) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy NovoCure stock right now, as the outlook appears bearish.

What are some stocks similar to NovoCure (NVCR) that investors often compare it to?
NovoCure (NVCR) is often compared to similar stocks such as Dentsply, Intuitive Surgical, LeMaitre Vascular, ICU Medical and Hologic.

What is the forecast for NovoCure's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast NovoCure's stock price to be around $17.41 in 2026. Starting from the current price of $18.86, this represents a 7.7% change in price, indicating a bearish outlook for the stock.

How to buy NovoCure (NVCR) Stock?
NovoCure stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy NovoCure shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.